行情

ZIOP

ZIOP

ZIOPHARM肿瘤
NASDAQ

实时行情|Nasdaq Last Sale

4.640
-0.340
-6.83%
盘后: 4.600 -0.04 -0.86% 16:12 01/17 EST
开盘
5.00
昨收
4.980
最高
5.03
最低
4.615
成交量
207.20万
成交额
--
52周最高
7.25
52周最低
1.920
市值
8.40亿
市盈率(TTM)
6.89
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ZIOP 新闻

  • ZIOPHARM Oncology Option Alert: Jul 17 $6 Calls Sweep (2) near the Ask: 20000 @ $1.2 vs 57 OI; Earnings 3/3 After Close [est] Ref=$4.68
  • Benzinga.3天前
  • ZIOPHARM Oncology Option Alert: Jul 17 $5 Calls Sweep (2) near the Ask: 500 @ $1.0 vs 176 OI; Ref=$4.47
  • Benzinga.01/02 16:25
  • ZIOPHARM Oncology Option Alert: Jan 17 $5.5 Calls Sweep (28) near the Ask: 1041 @ $0.201 vs 4036 OI; Ref=$4.9
  • Benzinga.2019/12/30 16:40
  • Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock
  • Zacks.2019/12/30 13:56

更多

所属板块

生物技术和医学研究
-0.10%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

ZIOP 简况

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
展开

Webull提供ZIOPHARM Oncology Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。